3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Unknown
1
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Colorectal Neoplasms
7
Recurrence
2
Prostatic Neoplasms
2
Neoplasms
2
Colonic Neoplasms
2
Smoking Cessation
1
Pathologic Processes
1
Ovarian Cancer Prevention
1
Neuroma, Acoustic
1
Neurofibromatosis 2
1
Neoplasms by Site
1
Motor Activity
1
Lung Neoplasms
1
Leukemia, Myeloid, Chronic-Phase
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Leukemia, Hairy Cell
1
Intestinal Neoplasms
1
Intestinal Diseases
1
Inflammation
1
Gastrointestinal Neoplasms
1
Fallopian Tube Neoplasms
1
Disease Attributes
1
Digestive System Neoplasms
1
Digestive System Diseases
1
Colonic Diseases
1
Breast Neoplasms
1
Barrett Esophagus
1
Adenocarcinoma Of Esophagus
1
Interventions
durvalumab
3
selpercatinib
2
palbociclib
2
Gonadotropin-Releasing Hormone
2
Cisplatin
2
Anastrozole
2
AZD9833
2
ribociclib
1
pembrolizumab
1
gallium 68 PSMA-11
1
ceralasertib
1
camrelizumab
1
anlotinib
1
abemaciclib
1
Taxes
1
Surgical Procedures, Operative
1
Sunitinib
1
Radiotherapy, Intensity-Modulated
1
Pemetrexed
1
Paclitaxel
1
Nimorazole
1
Letrozole
1
Immunotherapy
1
Fulvestrant
1
CP protocol
1
Aspirin
1
1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine
1
(225)Ac-PSMA-617
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Neoplasms by Site
×
Aspirin
×
Clear all
NCT03464305
2024-03-19
ASPIRIN
University Hospital, Antwerp
Phase 3
Active not recruiting
148 enrolled